Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 3/20 | 0.42 |
| ▸ | ITGAV | P06756 | 2/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5866425 | 1.00 | NPC1 (0.49) | NPC1RAB9AHPGDSMN1; SMN2POLB | |
| SCHEMBL6665274 | 0.85 | SLC6A2 (0.48) | NPC1RAB9AHPGDSMN1; SMN2HTT | |
| SCHEMBL6665281 | 0.85 | SLC6A2 (0.48) | NPC1RAB9AHPGDSMN1; SMN2HTT | |
| SCHEMBL7046825 | 0.85 | MCHR1 (0.44) | HPGDSMN1; SMN2POLBHTTSLC6A2 | |
| SCHEMBL5866353 | 0.85 | MCHR1 (0.44) | HPGDSMN1; SMN2POLBHTTSLC6A2 | |
| SCHEMBL8554659 | 0.84 | HPGD (0.45) | NPC1RAB9AHPGDSMN1; SMN2S1PR4 | |
| SCHEMBL7045680 | 0.83 | TACR2 (0.47) | NPC1RAB9AHPGDSMN1; SMN2HTT | |
| SCHEMBL5866364 | 0.83 | TACR2 (0.47) | NPC1RAB9AHPGDSMN1; SMN2HTT | |
| SCHEMBL7968837 | 0.83 | SMN1; SMN2 (0.61) | NPC1RAB9ASMN1; SMN2GPR139EPHX2 | |
| SCHEMBL8783374 | 0.80 | P2RX7 (0.49) | HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0739891-B1 | Substituted heterocycles | ASTRAZENECA AB (SE) | 2005-01-19 | — | — | EP | disclosed |
| US-20040248914-A1 | Method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | disclosed |
| EP-1450805-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030187255-A1 | Therapeutic heterocycles | MILLER SCOTT CARSON (US) | 2003-10-02 | — | — | US | disclosed |
| WO-2003037341-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| US-6444809-B1 | ANTIHISTAMINES | ZENECA LIMITED (GB) | 2002-09-03 | — | — | US | disclosed |
| US-6355695-B1 | ANTIHISTAMINES; ASTHMA THERAPY | ZENECA LIMITED (SE) | 2002-03-12 | — | — | US | disclosed |
| US-6235757-B1 | ANTIHISTAMINES | ZENECA LIMITED (GB) | 2001-05-22 | — | — | US | disclosed |
| US-6124279-A | NEUROKININ A ANTAGONISTS, ANTIASTHMATIC AGENTS | ZENECA LIMITED (GB) | 2000-09-26 | — | — | US | disclosed |
| US-6051580-A | Substituted heterocycles | ZENECA LIMITED | 2000-04-18 | — | — | US | disclosed |
| US-5990130-A | NOVEL 4-SUBSTITUTED PIPERIDINE DERIVATIVES WHICH ANTAGONIZE NEUROKININ; USEFUL IN TREATMENT OF ASMTHMA AND RELATED CONDITIONS | ZENECA LIMITED (GB) | 1999-11-23 | — | — | US | disclosed |
| US-5889024-A | Substituted heterocycles | ZENECA LIMITED (GB) | 1999-03-30 | — | — | US | disclosed |
| US-5861392-A | NONPEPTIDE ANTAGONISTS OF NEUROKININ A USEFUL FOR THE TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1999-01-19 | — | — | US | disclosed |
| US-5677317-A | Lactam compounds which are useful in the treatment of asthma | ZENECA LIMITED (GB) | 1997-10-14 | — | — | US | disclosed |
| EP-0739891-A2 | Substituted heterocycles | ZENECA LIMITED (GB) | 1996-10-30 | — | — | EP | disclosed |
| US-5567700-A | USEFUL FOR TREATING ASTHMA | ZENECA LIMITED (GB) | 1996-10-22 | — | — | US | disclosed |
| US-5534525-A | Lactam derivatives | ZENECA LIMITED (GB) | 1996-07-09 | — | — | US | disclosed |
| EP-0714392-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995012577-A1 | NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1995-05-11 | — | — | WO | disclosed |
| WO-1995005377-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248914-A1 | Method for the treatment of overactive bladder | TACR1, TACR2, OGFR | NPC1 3577/4885RAB9A 2716/4885HPGD 451/4885 |
| US-20030187255-A1 | Therapeutic heterocycles | BDKRB2, TK2, TACR2 | NPC1 387/4885RAB9A 2698/4885HPGD 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.